Supernus Pharmaceuticals, Inc. (SUPN)
|52 Week Range||26.64-42.09|
|1y Target Est||-|
|DCF Unlevered||SUPN DCF ->|
|DCF Levered||SUPN LDCF ->|
|Debt / Equity||4.59%||Neutral|
Upgrades & Downgrades
Latest SUPN news
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York Cit...
27 September 2023
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
8 August 2023
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare t...
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
8 August 2023
Supernus Pharmaceuticals (SUPN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.23. This compares to earnings of $0.14 per share a year ago.
Radcliffe Capital Management, L.P. Acquires Stake in Portage Fintech Acquisition Corp
27 July 2023
Radcliffe Capital Management, L.P. (Trades, Portfolio), a prominent investment firm, recently made a significant acquisition in the stock market.
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call ...
24 July 2023
ROCKVILLE, Md., July 24, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus: Rebuilding In Progress, But At An Inadequate Pace
12 June 2023
Supernus Pharmaceuticals faces declining revenues from its long-time top seller Trokendi XR due to generic competition. Despite Trokendi's struggles, Supernus reported a slim increase in aggregate qua...
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
10 June 2023
Supernus Pharmaceuticals is facing generic competition for its drug Trokendi. It's also scaling up its revenue for its medicine Qelbree.
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
9 May 2023
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Earnings Call Transcript
9 May 2023
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Ca...